Celebrated neurologist, psychiatrist and plant-medicine expert Dr. Dan Engle brings years of understanding of psychedelic medicine into research with Mind Cure.
VANCOUVER, BC, Feb. 17, 2021 – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“Mind Cure” or the “Company”) is pleased to announce the engagement of Dr. Dan Engle as Mind Cure’s Primary Investigator Consultant. Dr. Engle is Board Certified in Psychiatry and Neurology, with a clinical practice that combines functional medicine, integrative psychiatry, neuro-cognitive restoration. He is celebrated for contribution to understanding of traumatic brain injury and concussion recovery with his book The Concussion Repair Manual. Dr. Engle is transitioning from his previous role as an advisor to Mind Cure.
Mind Cure has identified traumatic brain injury (“TBI“) as a priority indication which shares important biological pathways1 associated to pain.2 Mind Cure will investigate the therapeutic potential of psychedelic compounds for TBI and related conditions. Dr. Engle will facilitate the translation of Mind Cure’s traumatic brain injury research from pre-clinical to clinical.
“Mind Cure is fortunate that Dr. Engle has chosen to bring his expertise and clinical experience with trauma and head injury to lead Mind Cure’s research efforts,” said President and CEO Kelsey Ramsden. “Dr. Engle is a trusted resource whose guidance will be pivotal in leading this transformative research program. TBI issues not only affect individuals but also can have lasting effects on families and communities”.
Traumatic brain injuries are a major cause of death and disability in North America and are increasing in number. From 2006 to 2014, the number of TBI-related emergency department visits, hospitalizations, and deaths increased by 53%. An average 32,000 people in the United States have died each day from injuries that include a traumatic brain injury. Those who survive can face effects that last a few days or the rest of their lives, and can include issues related to emotional functioning (e.g., personality changes, depression) along with impairments related to thinking or memory, movement and sensations, such as vision or hearing.3
About Dr. Dan Engle
Dr. Dan Engle is Medical Director of Kuya Institute for Transformational Medicine, consultant to numerous international plant-based healing and recovery centers. Specializing in psychiatry and neurology, Dr. Engle’s clinical practice is based on regenerative medicine, orthomolecular psychiatry, integrative spirituality, and peak performance methods. His 2017 book The Concussion Repair Manual, a guidebook to recovering from traumatic brain injury, is celebrated by physicians and professional athletes alike. His subsequent Full Spectrum Medicine program accelerates healing by combining traditional medical practices with neuro-regenerative medical technologies, including psychedelic medicines. With dozens of appearances on popular podcasts like The Joe Rogan Experience and The Tim Ferriss Show, Dr. Engle is a widely regarded thinker on both the subjects of psychedelic medicine and traumatic brain injury.
About Mind Cure Health Inc.
Mind Cure exists as a response to the current mental health crisis and urgent calls for effective treatments. Mind Cure believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.
Mind Cure is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. Mind Cure is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.
On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995
Forward-Looking Information
Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: Mind Cure investigating the therapeutic potential of psychedelic compounds for TBI and related conditions; Dr. Engle facilitating Mind Cure’s traumatic brain injury research from pre-clinical to clinical; the effect of Dr. Engle’s guidance on leading the transformative research program; and Dr. Engle transitioning to a new role from his previous role as an advisor.
Forward-looking information is based on a number of key expectations and assumptions made by Mind Cure, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and Mind Cure’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect Mind Cure’s business; there will be a demand for Mind Cure’s products in the future; TBI and related conditions will continue to cause a need for research related to the potential of psychedelic compounds for TBI and related conditions; Dr. Engle’s contributions will be pivotal in leading the transformative research program at Mind Cure; no unanticipated expenses or costs arise; Mind Cure will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; the addition of Dr. Engle as a Primary Investigator Consultant will help Mind Cure research the therapeutic potential and explore treatment processes associated with psychedelic compounds to assist in the Company’s mission to treat mental health issues; and Mind Cure will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what Mind Cure believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.
Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, Mind Cure’s industry and Mind Cure’s business, which may negatively impact, and may continue to negatively impact, Mind Cure and may materially adversely affect Mind Cure’s investments, results of operations, financial condition, and Mind Cure’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; the addition of Dr. Engle as a Primary Investigator Consultant may not help Mind Cure’s research and exploration of psychedelic compounds to achieve Mind Cure’s mission; Mind Cure’s research may not be able to significantly address TBI and related conditions or at all; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect Mind Cure can be found under “Risk Factors” in Mind Cure’s final prospectus which is available on SEDAR at www.sedar.com.
The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to Mind Cure. The forward-looking information is stated as of the date of this news release and Mind Cure assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.
The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.
SOURCE Mind Cure Health Inc.
Connect: Investor Relations: investors@mindcure.com; 1-888-593-8995
1 For e.g., Morgana D. da Silva, Giselle Guginski, Karina L. Sato, Luciana Sayuri Sanada, Kathleen A. Sluka, Adair R.S. Santos, Persistent pain induces mood problems and memory loss by the involvement of cytokines, growth factors, and supraspinal glial cells, Brain, Behavior, & Immunity – Health, Volume 7, 2020,100-118.
2 Jovanovic F, Candido KD, Knezevic NN. The Role of the Kynurenine Signaling Pathway in Different Chronic Pain Conditions and Potential Use of Therapeutic Agents. Int J Mol Sci. 2020 Aug 22;21(17):6045. doi: 10.3390/ijms21176045. PMID: 32842609; PMCID: PMC7503462.
3 Peterson AB, Kegler SR. Deaths from Fall-Related Traumatic Brain Injury — United States, 2008–2017. MMWR Morb Mortal Wkly Rep 2020;69:225–230.